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Hexadecafluorinated zinc phthalocyanine: photodynamic properties
against the EMT-6 tumour in mice and pharmacokinetics using 65Zn as a
radiotracer
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Summary Hexadecafluorinated zinc phthalocyanine (ZnPcF,6), an analogue of zinc phthalocyanine (ZnPc) in
which all hydrogen atoms have been substituted by fluorine, was prepared as a single isomeric product via the
condensation of tetrafluorophthalonitrile with zinc acetate. Fluorination renders the ZnPc soluble in most
common solvents. The photodynamic properties and pharmacokinetics of the ZnPcF,6 were evaluated in
EMT-6 tumour-bearing Balb/c mice using 65Zn-radiolabelled analogues. Both dyes, administered i.v. at
fLmol kg-' as Cremophor emulsions, revealed good tumour uptake [approximately 8-9 per cent of the
injected dose per g tissue (%ID g-')] at 24 h post injection (p.i.), with the fluorinated dye reaching higher
concentrations (approximately 11%ID g-') at 48 h p.i. and subsequently higher tumour-blood ratios due to
rapid blood clearance. ZnPcF,6 at a dose of 5 pmol kg-' (4.3 mg kg-') induced complete tumour regression
after phototherapy (24 h p.i., 650 -700 nm band, 360 Jcm-2, 200 mW cm-'). At a dose of 2fimol kg-' and
phototherapy at 24 h p.i., the tumour volume doubling time increased to 11 days vs 6 days for the control
tumours. A similar tumour growth delay was observed when phototherapy was conducted at 48 h or 72 h after
dye injection implying that tumour response correlates with tumour dye concentrations rather than serum
concentrations. As a result of its low solubility, the administered dose of ZnPc was limited to 1 fimol kg-' and
at this drug level significant tumour response was only observed when the dye was solubilised as the
pyridinium salt. Isolation of the neoplastic cells after in vivo dye administration and in vitro exposure to red
light followed by a colony formation assay showed that the ZnPcF,6 exhibited a 1-2 order of magnitude
higher potential for direct cell killing as compared with Photofrin and about a five times lower efficiency than
ZnPc. However, all three photosensitisers induced complete occlusion of tumour vasculature immediately after
PDT, suggesting that tumour regression mainly resulted from vascular stasis. The ZnPcF,6 offers several
advantages over ZnPc for clinical applications, including improved solubility in most solvents, resulting in
facilitated drug formation, favourable pharmacokinetics as well as the potential use in fluorine magnetic
resonance (F-MR) imaging.
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Phthalocyanines (Pcs) are among the various classes of dyes
that have been proposed as sensitisers to supersede
haematoporphyrin derivative (Photofrin II), currently used
for clinical photodynamic therapy (PDT) of cancer (van Lier,
1990; Rosenthal, 1991). This is due to the superior molar
absorptivity of these compounds (a> I05 M-1 cm-' when
fully monomerised), at wavelengths permitting greater pene-
tration of light in normal tissues (typically 670-680 nm),
when compared with Photofrin (e 10' M-1cm-1 at
630 nm). As a result of the extremely low solubility of
unsubstituted Pcs in most common solvents, much of the
research into the use of Pcs as photodynamic sensitisers has
concentrated on sulphonated derivatives, which are soluble in
polar solvents (e.g. water and/or alcohol). Methods for syn-
thesis of sulphonated Pcs, however, often yield complex mix-
tures composed of different levels of substitution and
regioisomers (Ali et al., 1988).
Among the non-substituted Pcs, zinc phthalocyanine
(ZnPc) has been investigated as a possible second generation
PDT sensitiser (Ginevra et al., 1990; Reddi et al., 1990). The
material is highly insoluble in most common solvents and a
proprietary liposomal formulation has been advanced for
clinical trials (Schieweck et al., 1994). To overcome such
solubility problems we proposed the fluorinated analogue of
ZnPc as a sensitiser for PDT (Boyle and van Lier, 1991).
Hexadecafluorinated zinc phthalocyanine (ZnPcF,6) (Figure
1) can be conveniently synthesised, in one step, from com-
mercially available starting materials, yielding a symmetrical
product without isomers. Fluorine is similar in size to hyd-
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rogen and can mimic hydrogen in biological environments,
and lipid solubility is increased, which may lead to enhanced
interaction with membranes. The fluorine atoms on ZnPcF,6
impart sufficient solubility on the molecule to allow stable
injectable aqueous emulsions to be prepared and offer the
potential for F-MR imaging or spectroscopy.
In this study we compare the biodistribution pattern of
ZnPc and ZnPcF16 formulated as Cremophor emulsions,
using the 65Zn isotope as a y-emitting tracer. In vivo
photodynamic properties are evaluated and some mechanistic
aspects of the tumour response are addressed.
Materials and methods
Synthesis
ZnPcF,6 (Figure 1) was synthesised by condensation of
tetrafluorophthalonitrile (Aldrich, Milwaukee, USA) with
zinc acetate dihydrate (1:1) at 160°C for 3 h (Birchall et al.,
1970; Boyle and van Lier, 1991). The crude compound was
purified by suspension in aqueous hydrogen chloride (2 M)
followed by filtration, washing of the residue with ethanol,
and extraction into acetone. Finally the product was passed
through a short column of silica gel eluting with acetone.
Removal of the solvent gave ZnPcF,6 in 50-60% yield (mol.
wt. 866). Absorption spectrum (pyridine): Amax (log
£) = 678 nm (5.3), 650 (4.67), 630 (4.56), 612 (4.51), 376
(4.56); Mass spectrum fast atom bombardment (FAB)
M+ = 866; '9F NMR (Bruker ARX 400, DMSO-d6, internal
standard TFE): - 156.66 (brs); - 149.01, - 148.97 (d);
- 145.65 (brs); - 143.50, - 143.47 (d); Anal. calculated for
C32F16N8Zn: C, 44.32; N, 12.94. Found: C, 44.35; N, 12.16.
Zinc phthalocyanine (ZnPc) was purchased from EastmanFluorinated zinc phthalocyanine
P"%_ RW Boyle et al
F
F F
F
F
Figure I Chemical structure of zinc hexadecafluorophthal-
ocyanine (ZnPcF]6).
Kodak (mol. wt. 578). Photofrin II was obtained from QLT,
Vancouver, BC, Canada.
[65Zn]ZnPcF,6 was synthesised using similar conditions as
for the synthesis of ZnPcF,6 as described above, but with the
inclusion of 65ZnC12 (300 iCi) (Amersham) in 1 M HCl. The
amount of radioactivity employed was kept low in order to
minimise problems in handling and disposal of the 65Zn
(tt = 34.9 weeks; = 1.116 MeV). The 65ZnCI2 was converted
into 65Zn(OAc)2 by drying under a stream of nitrogen fol-
lowed by addition of an aqueous sodium acetate buffer (1 ml;
1O mM, pH 7) and zinc acetate dihydrate (0.35 mmol). The
solution was again dried under nitrogen and the resulting
solid was added to the reaction mixture. Purification was as
for ZnPcF,6. The purified radiolabelled product was charac-
terised by absorption spectroscopy and y-counting. To
prepare [65Zn]ZnPc, 65ZnC12 (300pCi) in 1 M HCl was again
converted into 65Zn(OAc)2 as described above and subse-
quently added to 1,2-dicyanobenzene (45 mg; 0.35 mmol) and
zinc acetate dihydrate (77 mg; 0.35 mmol). The mixture was
then heated to 180NC for 3 h. After cooling the blue-green
product was dissolved in concentrated sulphuric acid (10 ml),
and reprecipitated by pouring into water (20 ml). The
[65Zn]ZnPc was recovered by centrifugation, washed with
water (30 ml) and ethanol (30 ml), then dried to give a
purple-blue powder. Specific activities of both 65Zn-labelled
dyes were adjusted with the cold analogue as detailed under
drug formulation.
Drugformulation
ZnPcF16 and ZnPc, and their 65Zn analogues were prepared
for injection by dissolution in acetone and 1-methyl-2-
pyrrolidinone or pyridine respectively (10 ml), the concentra-
tion being adjusted with the corresponding non-radioactive
ZnPcF,6 or ZnPc to achieve a final concentration of 127 tIM
and a sp. act. of 0.5 Ci mol -. Cremophor EL (Sigma, St
Louis, MO, USA) (1 ml) and propane-1,2-diol (Sigma)
(0.3 ml) were added to each solution, and the solvent was
removed by evaporation in vacuo. Finally sterile aqueous
sodium chloride (8.7 ml; 0.154M) was added, and solutions
were sonicated and filtered (0.45 rm; Millipore) to give a
homogeneous emulsion. Photofrin II was supplied as a
freeze-dried powder and dissolved in 5% dextrose
(1.25mgml-') before use.
Biodistribution
All experiments were performed on BALB/c mice (20-25 g)
(Charles River). Animal experiments were conducted follow-
ing the recommendations of the Canadian Council on
Animal Care and an in-house ethics committee. The animals
were allowed free access to water and food throughout the
course of the experiments. Mice had one tumour trans-
planted into the right hind thigh by intradermal injection of
2 x 105 EMT-6 cells suspended in 0.05 ml of Waymouth's
medium (Gibco). Animals were used 6-9 days p.i. when
tumours had reached a diameter of 3-5 mm with an average
volume of 16.6 mm3 (s.e.m. 0.8). [65Zn]ZnPcF,6 and [65Zn]-
ZnPc (0.2 ml; 25 nmol; 13 nCi) were injected i.v. via the
caudal vein, corresponding to a drug dose of 1.0ytmol kg-'.
At appropriate time intervals animals were sacrificed, blood
was collected and tissues of interest were removed, washed
with 0.154 M aqueous sodium chloride, blotted dry and
placed in pre-weighed tubes. Tubes were sealed to avoid loss
of moisture. Radioactivity of the samples, together with an
aliquot of the injected preparation, were counted, and
activities were calculated and expressed as the percentage of
the injected dose per gram of tissue (%ID g-'). For excretion
studies mice were placed in metabolic cages and faeces and
urine were collected and pooled.
Photodynamic therapy
Mice were prepared as for biodistribution studies (see above)
except that two tumours were grown, one on each hind thigh.
The right tumour was irradiated while the left (control)
tumour was shielded from light. Animals were injected via
the tail vein, with 5.0, 2.0 or 1.0timol kg-' ZnPcF,6 for-
mulated in Cremophor, as described above. Because of its
insolubility, ZnPc was studied at I ytmol kg-' only. After 24,
48 or 72 h the tumour on the right thigh was irradiated with
an 8 mm circular light beam of red light (650-700 nm;
360 J cm-2 at a fluence rate of 200 mW cm-2) delivered by a
1000 W xenon lamp fitted with 10 cm water filter, and LS700
and LL650 (Corion) filters. In the case of Photofrin II a
band of 600-650 nm was used at the same fluence, and
fluence rate, using LS650 and LL600 (Corion) filters.
Tumour response was assessed qualitatively and followed
from initial necrosis (within 48 h), to cure and for a follow-
up period of 30 days. Tumour cure was defined as necrosis of
the tumour mass within 48 h after irradiation, followed by
regrowth of normal tissue in the treatment area and no
recurrence of the neoplasm up to 30 days post-irradiation.
For treatments resulting in incomplete response, tumour
volume was measured and the doubling time of the treated vs
control tumour was used as a quantitative parameter to
compare tumour responses with different protocols.
In vivo/in vitro test
BALB/c mice were prepared as for biodistribution and
photodynamic studies and injected with 2 or 10,tmol kg-' Pc
formulated in 10% Cremophor (as above), or 10 mg kg-'
Photofrin II in saline. At 24, 48 or 72 h p.i. animals were
sacrificed and the tumours were excised, minced and
enzymatically digested (30 min in calcium chloride, 10 mM;
proteinase K (Sigma), 6.5 U; micrococcal nuclease (Sigma),
3U; collagenase (Sigma) 17 U, in 10 ml Hanks' buffer
0.154 M aqueous sodium chloride solution). The digested
preparation was then filtered through a 200 mesh sieve and
centrifuged at 600 g for 5 min. Two hundred cells were placed
in 6-cm Petri dishes and incubated for 3 h at 37°C in 5%
carbon dioxide in Waymouth's culture medium to allow
adhesion to the support. Cells were illuminated with red light
from two 500 W tungsten-halogen lamps (Sylvania FCL)
fitted with circulating, refrigerated filter containing aqueous
rhodamine [optical density (OD)580= 1.25] and a red filter
(26-4390, Ealing). Cells were illuminated with a fluence from
10 to 600 kJm2.
Vascular stasis assay
Animals were prepared as for PDT. Immediately following
irradiation mice were injected via the caudal vein with 2 mg
of sodium fluorescein in 0.2 ml of 0.154M aqueous sodium
chloride. After 2 min mice were sacrificed and placed under a
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Figure 2 Tissue concentration vs time profiles of [65Zn]ZnPcF16 ( E ) and [65Zn]ZnPc (LO) in per cent injected dose per g tissue
(1%ID g' = 0.25 nmol g-') (error<20%) in EMT-6 tumour-bearing BALB/c mice (n = 3). Dyes (0.2 ml; 25 nmol; 13 nCi) were
administrated i.v. at a dose of I pLmol kg-' in Cremophor-saline emulsions.
long wave UV lamp (320-400 nm; Amax = 365 nm) to
visualise areas penetrated by the dye. Any exclusion of
fluorescein from the irradiated area of tumour and surround-
ing tissue, relative to the control, was noted and photo-
graphed.
Results
Pharmacokinetics
Overall dye biodistribution pattern in the EMT-6 tumour-
bearing mice are presented in a 3-D plot of ZnPc and
ZnPcF,6 concentrations in per cent of the injected dose per g
(%ID g-') in various tissues vs time p.i. (Figure 2). Although
both dyes share similar distribution patterns, some quan-
titative differences are evident, reflecting significant
differences in lipophilicity and blood clearance pattern. Blood
concentrations as a function of time p.i. are also presented
separately as a semilog plot (Figure 3). It can be seen from
the area under the curves that the ZnPcF,6 initially (t<24 h)
has a higher bioavailability than the ZnPc. However, the
almost three times more rapid blood clearance of the
ZnPcF,6 (t, = 11 h) as compared with the ZnPc (t, = 30 h),
results in similar blood concentrations at 24 h p.i. (10-15
%ID g '), and subsequently (t>24 h) low blood concentra-
tions of the ZnPcF,6. Tumour concentrations together with
tumor-blood, tumour-skin and tumour-muscle ratios are
presented in Figure 4. The ZnPc reached a maximum concen-
tration of 8%ID g-' (2 nmolg-') at 24 h p.i., while the
ZnPcF,6 reached somewhat higher levels, e.g. 9, 11 and
8.5%ID g-', at 24, 48 and 72 h p.i. respectively (Figure 4).
The amounts of both dyes in muscle and skin was low,
resulting in favourable tumour-tissue ratios. The rapid
blood clearance of the ZnPcF,6 resulted in significantly
higher tumour-blood ratios at longer periods p.i. than those
observed with the ZnPc (Figure 4).
The route of excretion was similar for both dyes. During
the first 96 h p.i. of either [65Zn]ZnPc or [65Zn]ZnPcFI6, only
1% of the total injected dose of 65Zn radioactivity was col-
lected in the urine, whereas 24%ID was found in the faeces.
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Figure 3 Blood clearance of [65Zn]ZnPcF,6 (@) and [65Zn]ZnPc
(0) in tumour-bearing mice (see the legend of Figure 2 for
experimental conditions). Error bars represent the standard
deviation from the mean.
Photodynamic effects
At a drug dose of 5 Lmol kg-', (4.3 mgkg-') of ZnPcF,6
formulated in Cremophor, followed by PDT at 24 h p.i., four
out of five animals showed complete tumour regression. This
is similar to the effect of Photofrin II, which required a
minimal dose of 5 mgkg-' (PDT at 24 h p.i., n = 8) for a
similar tumour response, using the same fluence over
600-650 nm. With both preparations complete vascular
stasis in the tumour was evident immediately after PDT.
In order to correlate the pharmacokinetics of the ZnPcF,6
with the PDT efficacy, tumour growth was studied in more
detail by lowering the dye dose to 2lLmol kg-' and by vary-
ing the time interval between dye administration and PDT
from 24 h to 72 h. Tumour volume of both the control and
treated tumours were plotted as a function of time to yield a
growth curve from which the time (± s.e.m.) to reach a
100% increase in tumour volume was interpolated. PDT at
24h p.i. gave a doubling time of l1( ± 2) days vs 6 (± 1)
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Figure 4 Tumour uptake in %ID g-' (± s.d.) and tumour-
blood, tumour-muscle and tumour-skin ratios of [65Zn]ZnPcF,6
( _ ) and [65Zn]ZnPc ( 1 ) in tumour-bearing mice (see legend
of Figure 2 for experimental conditions).
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days for the control tumors (n = 7). PDT at 48 h p.i. gave a
doubling time of 11 (± 1) days vs 8 (± 1) days for the
controls (n = 8) and at 72 h p.i. the doubling time of the
treated tumors was 12 ( ± 1) days vs 8 ( ± 0.5) days for the
control tumours (n = 9). Although doubling time varied only
slightly with the delay in time interval between dye admini-
stration and PDT, none of the animals in the 24 h group
showed tumour cure, whereas 25% of the animals in the 48 h
and 72 h group were tumour free 21 days post treatment.
Owing to its low solubility, the unsubstituted ZnPc can only
be formulated to higher dye concentration when initially
dissolved in pyridine. Cremophor emulsions derived from
such solutions still contain traces of pyridine, which are
coordinated to the axial ligands of the central metal ion of
ZnPc, favouring the photodynamic potential of the ZnPc.
This formulation induced complete tumour regression at
2 ,tmol kg-' (1.2mg kg-') following PDT at 24 h p.i. with
complete vascular stasis in the tumour immediately after
illumination. Since pyridine is not accepted for clinical drug
formulation we also used 1-methyl-2-pyrrolidinone to initially
dissolve the ZnPc to yield concentrations of ZnPc in
Cremophor suitable for a maximum dye administration of
1 ytmol kg-'. However, at these dose levels the ZnPc
Cremophor emulsions did not induce a significant tumour
response following PDT (24 h p.i.).
In vitro phototherapy after in vivo dye administration
revealed different levels of photosensitivity of the tumour
cells after the different treatment protocols. The ZnPc
(pyridinium complex, Cremophor emulsion) had the highest
potential to inflict direct cell kill during PDT since a five
times lower in vivo dose, as compared with ZnPcF,6
(Cremophor emulsion), resulted in similar in vitro tumour cell
photosensitivity (Figure 5). Thus with ZnPc we obtained an
ex vivo LD90 = 50 J cm-2 (24 h p.i. of 2 jtmol kg-'), while
with ZnPcF,6 an ex vivo LD90 = 45 J cm-2 (24 h p.i. of
10[Lmolkg-') was observed (Figure 5). In agreement with
earlier reports (Henderson and Bellnier, 1989), the direct cell
killing potential of Photofrin was found to be extremely low.
Only 10% cell killing was observed with a fluence of
50 J cm-2 (24 h p.i. of 10mg kg-'). Variations in the ex vivo
LD90 of the ZnPcF,6 paralleled the in vivo dye uptake pattern
by the tumour, e.g. the lowest LD90 = 45 J cm-2 was
Figure 5 EMT-6 cell survival in tumours excised 24 h, 48 h and
72 h p.i. of photosensitiser. Cells were exposed to red light
(600-700 nm; 3-60 J cm2) 3 h after plating. Errors are expressed
as standard deviation from the mean. (a) Injected dose
10 jmol kg-' for 0, ZnPcFI6 (24 h); *, ZnPcF,6 (48 h); V,
ZnPcF,6 (72 h); V, PII (24 h). ZnPcF,6 and 10mg kg- for
Photofrin. (b) Injected dose 10ltmol kg-' for ZnPcF]6 and
10 mg kg- for Photofrin, and 2fLmol kg- for ZnPc. V, PII
(24 h); 0, ZnPcF,6 (24 h); 0, ZnPc (24 h).
observed at 48 h p.i. when tumour dye levels were at a
maximum, and identical LD90 = 70 J cm-2 were recorded at
24 and 72h p.i., when tumour dye concentrations were
lower, but similar (Figures 4 and 5).
Discussion
In this study we have evaluated the effect of fluorination on
the pharmacokinetic and photodynamic properties of ZnPc.
The biodistribution and PDT efficacy of ZnPc have
previously been studied extensively using standard liposomal
preparations (Reddi et al., 1987, 1990; Milanesi et al., 1990)
and ZnPc encapsulated in a proprietary liposomal prepara-
tion has been proposed for clinical trials (Schieweck et al.,
1994). Our tumour uptake and blood clearance data of the
[65Zn]ZnPc in CRM-emulsions are similar to the earlier
reported finding with liposomal ZnPc preparations (Reddi et
al., 1987). Partition between the carrier and various serum
proteins probably determines the fate of the dyes, suggesting
that similar blood transport and tumour uptake mechanism
are involved, regardless of the carrier. Low density lipo-
proteins (LDLs) have been implicated in the transport of
hydrophobic drugs and their preferential interaction with
endothelial and neoplastic cells of tumour tissue may, at least
in part, explain tumour selectivity (Goldstein et al., 1979;
Netland et al., 1988).
Increased solubility of the ZnPcF,6 vs ZnPc in various
common solvents allows for drug formulation in a wider
selection of vehicles. Thus in addition to CRM, we recently
showed that ZnPcF,6 can readily be formulated in biode-
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gradable polyethylene glycol-coated poly(lactic acid)
nanoparticles (PEG-coated PLA NP), resulting in advan-
tageous biodistribution and excretion pattern for PDT ap-
plications (Allemann et al., 1995). Topical application of
ZnPcF16 formulated in CRM also induced a good tumour
response in the EMT-6 tumour model, whereas ZnPc was
inactive under these conditions (Margaron et al., 1992).
The use of y-emitting 65Zn for quantification of the dyes
greatly facilitated the biodistribution studies since dye extrac-
tion was circumvented and problems with fluorescence quen-
ching were eliminated. Zn(II) is strongly chelated within the
Pc macrocycle cavity and no evidence was found for in vivo
dissociation of the 65Zn from the dye complexes. The proce-
dure however does not distinguish between concentrations of
photoactive-monomeric and inactive-aggregated forms of the
dye, which could result in overestimation of the photo-
dynamic potential based on 65Zn concentrations only. Also,
distribution patterns within the tumour compartment are not
visualised in this manner. It is obvious that dye localisation
at sensitive cellular components is more important for PDT
efficacy than high overall tissue concentrations. Tumour res-
ponse with ZnPcF16-PDT appears, however, directly related
to tumour dye levels rather than blood concentration. This is
demonstrated by comparing actual tissue concentrations and
tumour-blood ratios of the ZnPcF16 (Figure 4) with tumour
response following PDT at 24 h, 48 h and 72 h p.i. The
tumour volume doubling times of the treated tumours are
similar over these time intervals (11- 12 days vs 6-8 days for
control tumours), paralleling the stable tumour dye concen-
trations (9- 10%ID g-') over the 24-72 h p.i. time interval. In
contrast, blood ZnPcF16 concentrations decrease rapidly over
the same time interval, resulting in a large increase in
tumor-blood ratios between 24 h, 48 h and 72 h p.i. (Figure
4). The faster blood clearance of the ZnPcF16 as compared
with ZnPc should be advantageous for a clinical setting since
the presence of photosensitiser in the serum has been cor-
related with prolonged cutaneous photosensitivity, which is
considered a major side-effect of PDT (Zalar et al., 1977).
A correlation between in vivo dye levels and ex vivo
tumour cell photosensitivity appears to hold in regard to the
overall change in the dye concentration in the tumour over
time. Thus in the case of the ZnPcF16, tumour concentrations
vary from approximately 9%ID g-1 at 24 and 72 h p.i., to
11%ID g-' at 48 h p.i. The ex vivo cell photosensitivity
follows a similar pattern requiring approximately 70 J cm2
for 90% cell kill at 24 and 72 h, vs approximately 45 J cm2 at
48 h (Figure 5). These apparent variations in cell uptake will
probably not be restricted to tumour cells only. Differences
in uptake by endothelial cells and macrophages, between the
ZnPcF16 and ZnPc, also could explain their relative PDT
efficacy. Damage to these cells will trigger the release of
vasoactive biomolecules, which induce restriction of the small
vessels in the affected tissue, resulting in local shut-down of
the blood circulation (Henderson, 1990). In this regard it
should be noted that immediately after PDT with all three
dyes, vascular stasis is extensive, as demonstrated by ex-
clusion of fluorescein from the blood flow in the tumour
area. Such a pattern is characteristic of an indirect cell
damage mechanism and the resulting tumour regression has
been attributed to oxygen deprivation following vascular
stasis (Henderson, 1990). These considerations suggest that
the direct cell kill component of the tumour response after
either ZnPc- or ZnPcF16-mediated PDT, is not the principal
cause of tumour necrosis.
In summary, our data show that ZnPcF16 is a promising
photosensitiser for the PDT of cancer. Improved solubility of
the ZnPcF16, as compared with ZnPc, in most common
organic solvents renders this drug more amenable for for-
mulation in various vehicles, including water-oil emulsions
and nanoparticles. Finally, the presence of two sets of eight
chemically equivalent F atoms provide for strong '9F NMR
signals with potential applications in magnetic resonance
spectroscopy and imaging.
Abbreviations
PDT, photodynamic therapy; HPLC, high-performance liquid
chromatography; %ID, per cent of the injected dose; %ID g 1, per
cent of the injected dose per g tissue; p.i., post injection; CRM,
Cremophor; ZnPc, zinc phthalocyanine; ZnPcF16, zinc hex-
adecafluorophthalocyanine.
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